Biogen Inc.BIIB
NASDAQ • Healthcare
$172.97
P/E
19.64
PEG
—
FCF Yield
—
Rev Growth YoY
+222.0% YoY
Gross Margin
7569.0%
Health Score
6/10
D/E Ratio
0.34
Confidence
LOW
Business Snapshot
Biogen Inc. is a large-cap biotechnology and drug manufacturer listed on the NASDAQ, operating in the Healthcare sector with a focus on treatments for neurological, rare, and autoimmune diseases. The company's portfolio includes established therapies and newer product launches in areas such as Alzheimer's disease and multiple sclerosis. Based on a current share price of $172.97 and a 52-week trading range of $114.66–$202.41, Biogen sits in what historically qualifies as large-cap territory for a major pharmaceutical firm.
Financial Health
**Score: 6/10** Biogen's balance sheet shows disciplined leverage, with a Debt/Equity ratio of just 0.34x — well within conservative thresholds — and a Current Ratio of 2.68x, indicating the company can comfortably cover short-term obligations roughly 2.7 times over. Reported gross margin of 7,569% and net margin of 1,307% appear in the data but are almost certainly distorted by extraordinary accounting items (such as asset sales, revaluations, or one-time gains), and should not be taken as representative of underlying operating profitability...
Risk Assessment
- **EARNINGS QUALITY:** Earnings growth of -2,130.0% YoY alongside reported net margins of 1,307% and gross margins of 7,569% strongly indicates material accounting distortions, making true profitability assessment unreliable. - **DATA COMPLETENESS:** TTM Revenue, TTM Net Income, and Free Cash Flow are all unavailable, preventing a complete fundamental assessment of the business's current financial state. - **TECHNICALS:** The stock is trading below both its 50-day and 200-day moving averages, with a confirmed "death cross" pattern and a bearish MACD signal — all three technical indicators point in the same cautious direction. - **PRICE BELOW 52-WEEK HIGH:** At $172.97, Biogen is approximately 14.5% below its 52-week high of $202.41, reflecting meaningful price deterioration from recent peaks with no confirmed technical reversal signal. - **DCF UNCERTAINTY:** Free cash flow data is absent, rendering both the FMP and Python DCF models inoperative; intrinsic value cannot be estimated with any reasonable confidence. ---...